Skip to main content

Table 1 Cutoffs for greater or lesser clinical or functional response

From: Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy

 

Greater response

Lesser response

Clinical

 CDAI [10]

Remission (≤ 2.8) or LDA (> 2.8 to ≤ 10)

TA remission/LDA (≤ 10)

Moderate/high disease activity (> 10)

TA moderate/high disease activity (> 10)

 %∆CDAI [11]

 ≥ 85% decrease

Increase, or < 85% decrease

 ACR-N [11]

 ≥ ACR70

 < ACR70

Functional

 ∆HAQ-DI [14]

Decrease ≥ 0.22 (MCID)

Increase, or decrease < 0.22 (non-MCID)

 HAQ-DI [12, 13]

Normalized (< 0.5)

Not normalized (≥ 0.5)

  1. ∆, change from baseline; ACR70, American College of Rheumatology ≥ 70% response rate; ACR-N, American College of Rheumatology response rate, where ACR is the percentage improvement from baseline in American College of Rheumatology components, and N represents the minimum percentage achieved by each patient; CDAI, Clinical Disease Activity Index; HAQ-DI, Health Assessment Questionnaire-Disability Index; LDA, low disease activity; MCID, minimum clinically important difference; TA, time-averaged